iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. Its Zio XT monitor, a single-use, wire-free, and wearable patch-based biosensor, records patient's heartbeats and ECG data. The company was founded in 2006 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IRTC
CUSIPN/A
Phone415-632-5700
Debt
Debt-to-Equity Ratio0.45
Current Ratio6.59
Quick Ratio6.48
Price-To-Earnings
Trailing P/E Ratio-64.57
Forward P/E Ratio-52.97
P/E GrowthN/A
Sales & Book Value
Annual Sales$98.51 million
Price / Sales19.93
Cash FlowN/A
Price / CashN/A
Book Value$3.46 per share
Price / Book24.04
Profitability
EPS (Most Recent Fiscal Year)($1.30)
Net Income$-29,420,000.00
Net Margins-32.73%
Return on Equity-43.37%
Return on Assets-26.92%
Miscellaneous
Employees575
Outstanding Shares23,600,000
Market Cap$1,975.80
Irhythm Technologies (NASDAQ:IRTC) Frequently Asked Questions
What is Irhythm Technologies' stock symbol?
Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."
How were Irhythm Technologies' earnings last quarter?
Irhythm Technologies Inc (NASDAQ:IRTC) posted its quarterly earnings results on Wednesday, May, 2nd. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.11. The business earned $30.60 million during the quarter, compared to analysts' expectations of $29.07 million. Irhythm Technologies had a negative net margin of 32.73% and a negative return on equity of 43.37%. The company's quarterly revenue was up 43.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.24) EPS. View Irhythm Technologies' Earnings History.
When is Irhythm Technologies' next earnings date?
What price target have analysts set for IRTC?
7 brokerages have issued 1 year price targets for Irhythm Technologies' stock. Their forecasts range from $60.00 to $93.00. On average, they anticipate Irhythm Technologies' stock price to reach $79.50 in the next year. This suggests that the stock has a possible downside of 4.6%. View Analyst Ratings for Irhythm Technologies.
What is the consensus analysts' recommendation for Irhythm Technologies?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Irhythm Technologies stock?
Here are some recent quotes from research analysts about Irhythm Technologies stock:
- 1. According to Zacks Investment Research, "iRhythm Technologies, Inc. is a digital healthcare company. It focuses on the provision of ambulatory electrocardiogram, monitoring for patients at risk for arrhythmias primarily in the United States. The company offers ZIO Service, a platform which provides wearable biosensor with cloud-based data analytics that distill data from heartbeats into clinically actionable information. iRhythm Technologies, Inc. is headquartered in San Francisco, California. " (7/4/2018)
- 2. Northland Securities analysts commented, "We note that this was a physician-initiated study and funded by Bardy. Also, it is important to take this study within the context of an initial study which could provide clues for a larger head-head study, providing important clues for the sensitivity & specificity of R-R wave vs. P-wave analysis in ambulatory ECG monitoring." (4/16/2018)
- 3. Canaccord Genuity analysts commented, "We expect these data, assuming the read-out of the full study data follows suit (which we expect), will build IRTC’s case with payers, paving the way ultimately for prospective screening with Zio in a brand new, 3- million-patient TAM. While not in our model at all, we think over time, payors will cover Zio for screening of high-risk patients defined by the mSToPs study. We reiterate our BUY rating and $59 price target." (11/14/2017)
Who are some of Irhythm Technologies' key competitors?
Some companies that are related to Irhythm Technologies include Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Haemonetics (HAE), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Nevro (NVRO), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS) and Tandem Diabetes Care (TNDM).
Who are Irhythm Technologies' key executives?
Irhythm Technologies' management team includes the folowing people:
- Mr. Kevin M. King, Pres, CEO & Director (Age 62)
- Mr. Matthew C. Garrett, Chief Financial Officer (Age 50)
- Mr. David A. Vort, Exec. VP of Sales (Age 52)
- Dr. Derrick Sung, Exec. VP of Strategy & Corp. Devel. (Age 45)
- Ms. Judith C. Lenane RN, MHA, Chief Clinical Officer and Exec. VP of Operations (Age 59)
When did Irhythm Technologies IPO?
(IRTC) raised $76 million in an initial public offering (IPO) on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
Has Irhythm Technologies been receiving favorable news coverage?
News stories about IRTC stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Irhythm Technologies earned a news impact score of 0.18 on Accern's scale. They also assigned media headlines about the company an impact score of 44.31 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Irhythm Technologies' major shareholders?
Irhythm Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Xact Kapitalforvaltning AB (0.02%) and Amalgamated Bank (0.02%). Company insiders that own Irhythm Technologies stock include David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Raymond W Scott, Synergy Life Science Partners and Vijay K Lathi. View Institutional Ownership Trends for Irhythm Technologies.
Which institutional investors are buying Irhythm Technologies stock?
How do I buy shares of Irhythm Technologies?
Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Irhythm Technologies' stock price today?
One share of IRTC stock can currently be purchased for approximately $83.31.
How big of a company is Irhythm Technologies?
Irhythm Technologies has a market capitalization of $1.98 billion and generates $98.51 million in revenue each year. The company earns $-29,420,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. Irhythm Technologies employs 575 workers across the globe.
How can I contact Irhythm Technologies?
Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, SAN FRANCISCO CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]
MarketBeat Community Rating for Irhythm Technologies (NASDAQ IRTC)
MarketBeat's community ratings are surveys of what our community members think about Irhythm Technologies and other stocks. Vote "Outperform" if you believe IRTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
